1.Research advances in add-on treatment for negative symptoms and cognitive dysfunction in schizophrenia.
Ranran LI ; Gangrui HEI ; Ye YANG ; Renrong WU ; Jingping ZHAO
Journal of Central South University(Medical Sciences) 2020;45(12):1457-1463
Antipsychotic medication is the primary treatment for schizophrenia, which is effective on ameliorating positive symptoms and can reduce the risk of recurrence, but it has limited efficacy for negative symptoms and cognitive dysfunction. The negative symptoms and cognitive dysfunction seriously affects the life quality and social function for the patients with schizophrenia. Currently, there is plenty evidence that antipsychotic drugs combined with adjuvant therapy drugs can effectively improve the negative symptoms and cognitive dysfunction. These drugs include anti-oxidants, nicotinic acetylcholine receptors and neuro-inflammatory drugs (anti-inflammatory drugs, minocycline), which show potential clinical effects.
Anti-Inflammatory Agents/therapeutic use*
;
Antipsychotic Agents/therapeutic use*
;
Cognitive Dysfunction/etiology*
;
Humans
;
Minocycline/therapeutic use*
;
Schizophrenia/drug therapy*
2.Efficacy and safety of aripiprazole in the treatment of childhood tic disorders: a Meta analysis.
Qiong FANG ; Lang CHEN ; Qiao-Bing CHEN ; Fang YANG
Chinese Journal of Contemporary Pediatrics 2015;17(7):715-720
OBJECTIVETo evaluate the clinical efficacy and safety of aripiprazole in the treatment of childhood tic disorders (TD) by a meta analysis.
METHODSA systematic search for randomized controlled trials (RCTs) on the efficacy and safety of aripiprazole in the treatment of childhood TD that were published between January 2000 and August 2014 was conducted. A Meta analysis on the selected RCTs was conducted using Review Manager 5.2 software.
RESULTSSix RCTs involving 551 TD patients were enrolled. There were no significant differences in the efficacy between aripiprazole and traditional drugs for treatment of TD either by the end of follow-up visit or at 2 weeks, 4 weeks and 8 weeks after treatment. The subgroup analysis results indicated that aripiprazole had the same efficacy for the treatment of TD as traditional drug haloperidol. Aripiprazole had a lower incidence of extrapyramidal reactions than haloperidol (P<0.05), but the overall incidence of side effects of aripiprazole was not lower than traditional drugs for treatment of TD.
CONCLUSIONSThe available evidence suggests that aripiprazole has the same curative effect in the treatment of childhood TD compared with the traditional drugs. However, it is difficult to draw a firm conclusion that aripiprazole is a safer drug in the treatment of childhood TD.
Antipsychotic Agents ; therapeutic use ; Aripiprazole ; adverse effects ; therapeutic use ; Humans ; Tic Disorders ; drug therapy
3.Aripiprazole in the treatment of acute episode of schizophrenia: a real-world study in China.
Qian LI ; Yun'ai SU ; Xuemei LIAO ; Maosheng FANG ; Jianliang GAO ; Jia XU ; Mingjun DUAN ; Haiying YU ; Yang YANG ; Zhiyu CHEN ; Jintong LIU ; Shaoxiao YAN ; Peifen YAO ; Shuying LI ; Changhong WANG ; Bin WU ; Congpei ZHANG ; Tianmei SI
Chinese Medical Journal 2023;136(9):1126-1128
5.A case report on the relationship between treatment-resistant childhood-onset schizophrenia and an abnormally enlarged cavum septum pellucidum combined with cavum vergae.
Zheng-luan LIAO ; Shao-hua HU ; Yi XU
Chinese Medical Journal 2012;125(7):1349-1351
The treatment of refractory schizophrenia has been a clinical challenge for most psychiatrists; the possible reasons include diagnostic errors, medical conditions and brain dysgenesis. Here, we described a patient with childhood-onset schizophrenia who had severe psychiatric symptoms such as auditory hallucinations and persecutory delusions, and etc. We reexamined all his possible medical conditions and found that the patient had an abnormally enlarged cavus septum pellucidum (CSP) combined with cavum vergae (CV) (maximum length >30 mm). Some reports suggested that abnormal CSP (length >6 mm) has a significant association with schizophrenia. However, abnormally large CSP or CSP/CV and related prognosis were reported rarely. This case suggested that abnormally enlarged CSP or CSP/CV may worsen the prognosis.
Adolescent
;
Antipsychotic Agents
;
therapeutic use
;
Benzodiazepines
;
therapeutic use
;
Clozapine
;
therapeutic use
;
Dibenzothiazepines
;
therapeutic use
;
Humans
;
Male
;
Quetiapine Fumarate
;
Schizophrenia, Childhood
;
diagnosis
;
drug therapy
;
pathology
;
Septum Pellucidum
;
pathology
6.MiRNA-365 and miRNA-520c-3p respond to risperidone treatment in first-episode schizophrenia after a 1 year remission.
Sha LIU ; Yan-bo YUAN ; Li-li GUAN ; Hui WEI ; Zhang CHENG ; Xue HAN ; Lei YANG ; Cheng-cheng PU ; Fu-de YANG ; Zheng LU ; Hong DENG ; Jing-ping ZHAO ; Xin YU
Chinese Medical Journal 2013;126(14):2676-2680
BACKGROUNDMicroRNAs (miRNAs) control gene expression by destabilizing target transcripts and inhibiting their translation. Aberrant expression of miRNAs has been described in many human diseases, including schizophrenia. However, the effects on miRNA expression in response to antipsychotic treatment in peripheral circulation have not been thoroughly examined.
METHODSUsing quantitative real-time PCR (qRT-PCR), We quantified the expression of seven candidate miRNAs in plasma samples of 40 first-episode schizophrenics before and after antipsychotic treatment. The patients were all treated with risperidone and achieved remission in 1 year.
RESULTSCompared with the baseline, the expression levels of miR-365 and miR-520c-3p were significantly down-regulated after 1 year of risperidone treatment (P < 0.001). There were no significant correlations between the clinical symptoms and the expression levels of these two miRNAs (P > 0.05).
CONCLUSIONSThis study analyzed possible circulating miRNAs in response to antipsychotic monotherapy for schizophrenia, the further mechanism need to be confirmed.
Adult ; Antipsychotic Agents ; therapeutic use ; Female ; Humans ; Male ; MicroRNAs ; blood ; Risperidone ; therapeutic use ; Schizophrenia ; drug therapy ; genetics
7.A Meta-analysis of the effectiveness of risperidone versus traditional agents for Tourette's syndrome.
Wentao CHENG ; Li LIN ; Shaonan GUO
Journal of Central South University(Medical Sciences) 2012;37(4):359-365
OBJECTIVE:
To evaluate the efficacy and safety of risperidone versus traditional agents in treating Tourette's syndrome.
METHODS:
Randomized, controlled trials (RCTs) of risperidone versus traditional agents for Tourette's syndrome were identified, and eligible studies were included according to our established strategy. Besides methodological quality of inclusive trials, assessed by the Jadad scale, heterogeneity test, Meta-analysis, funnel plot analysis, subgroup analysis and sensitivity analysis were used to analyze the data.
RESULTS:
A total of 12 RCTs were included, with most trials of low methodological quality and high heterogeneity. Meta-analysis from 11 of the identified RCTs, involving total 741 patients, showed that there was no significant difference in efficacy between risperidone and traditional agents, based on the results of sensitivity analysis, and analyses of a haloperidol subgroup and a domesticforeign subgroup. The funnel plots was approximately symmetrical, indicating little publication bias. Risperidone presented mild side effects overall, including extrapyramidal symptoms (EPS), autonomic nervous system symptoms, toxic reactions and the Treatment Emergent Symptom Scale (TESS) score of the treatment group were significantly less than those of control.
CONCLUSION
Risperidone appears to have the same efficacy and appropriate safety as traditional agents in treating Tourette's syndrome. Because of the low validity of the results, we are searching for support from the more RCTs with higher methodological quality.
Antipsychotic Agents
;
adverse effects
;
therapeutic use
;
Humans
;
Randomized Controlled Trials as Topic
;
Risperidone
;
adverse effects
;
therapeutic use
;
Tourette Syndrome
;
drug therapy
8.Optimal Treatment Strategies of Clozapine for Refractory Schizophrenia.
Yuan-Yuan LI ; Yun-Shu ZHANG ; Jian WANG ; Ke-Qing LI ; Hong-Ying WANG
Acta Academiae Medicinae Sinicae 2016;38(6):666-678
Objective To systematically evaluate the efficacy of clozapine combined with other antipsychotic drugs in the treatment of refractory schizophrenia. Methods We searched Medline, EMBASE, and China Biology Medicine databases in both English and Chinese for randomized controlled trials, quasi-randomization controlled trials, and clinical controlled trials concerning the combinations of clozapine with other antipsychotic drugs for refractory schizophrenia. Quality assessment and data extraction were conducted with the Cochrane collaboration's RevMan 5.3 software. Results Totally 47 trials met the inclusion criteria, in which clozapine was combined with risperidone, aripiprazole, sulpiride, ziprasidone, modified electroconvulsive therapy, valproate, or lithium carbonate, respectively. Analysis showed that most combination strategies were superior to clozapoine alone (P<0.05), except for the combination with lithium carbonate(8 weeks: RR=1.27, 95%CI=0.82-1.97,P=0.28; 12 weeks: RR=1.53, 95% CI=0.45-5.13, P=0.49). Conclusion Reasonable combination of clozapine with other drugs may improve the therapeutic effectiveness and reduce adverse reactions and thus can be effectively used for treating refractory schizophrenia.
Antipsychotic Agents
;
therapeutic use
;
Benzodiazepines
;
China
;
Clozapine
;
therapeutic use
;
Drug Therapy, Combination
;
Humans
;
Randomized Controlled Trials as Topic
;
Schizophrenia
;
drug therapy